Plausibly Exogenous [1809] - Market Exclusivity (01/15/2025)

LHS Variable
Pharmaceutical innovation

RHS Variable
Market exclusivity periods

Source of Exogenous Variation
Generating Antibiotic Incentives Now (GAIN) Act, which granted five additional years of exclusivity for antibiotics but not antivirals or vaccines

- Kong and Zhao (2024), “Market Incentives and the Drug Development Pipeline: Evidence from Antibiotics”